AI assistant
Werewolf Therapeutics, Inc. — Director's Dealing 2021
May 4, 2021
34192_dirs_2021-05-04_e99008b2-c08a-44c7-aa31-55c53ca2fef5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2021-05-04
Reporting Person: Sphera Global Healthcare Management LP (10% Owner)
Reporting Person: Sphera Global Healthcare GP Ltd. (10% Owner)
Reporting Person: SPHERA FUNDS MANAGEMENT LTD. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-04 | Common Stock | C | 312997 | — | Acquired | 312997 | Indirect |
| 2021-05-04 | Common Stock | P | 475000 | $16 | Acquired | 787997 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-04 | Series B Preferred Stock | $ | C | 2713410 | Disposed | Common Stock (312997) | Indirect |
Footnotes
F1: Includes (a) 187,798 shares held by Sphera Global Healthcare Master Fund (the "Healthcare Fund") and (b) 125,199 shares held by Sphera
Biotech Master Fund, LP (the "Biotech Fund" and, together with the Healthcare Fund, the "Funds").
F2: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F3: Sphera Global Healthcare Management LP is the investment manager for the Funds (the "Management Company"). The Management Company is managed, controlled and operated by its general partner Sphera Global Healthcare GP Ltd. (the "General Partner"), of which Sphera Funds Management Ltd. ("SFML") is the controlling shareholder. Each of the Management Company, the General Partner and SFML may be deemed the indirect beneficial owner of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended.
F4: Includes (a) 300,000 shares held by the Healthcare Fund and (b) 175,000 shares held by the Biotech Fund.
F5: Includes (a) 487,798 shares held by the Healthcare Fund and (b) 300,199 shares held by Biotech Fund.